not tagged
not tagged
['lymsm', 'dlbcl']
adapted treatment of high risk dlbcl (tp53mut, myc-r, dhl, del, cd5+) #17icml
- complicated tx workflow
- no difference in outcomes (??) compared to historical controls
unclear what this adds to #lymsm armamentarium. 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈